Lexaria Bioscience Enters Warrant Exercise Financing, Raises ~$5.9M

What Happened

• On September 7, 2026, Lexaria Bioscience Corp. (LEXX) entered into inducement offer letters prompting certain holders to immediately exercise existing warrants to buy up to 453,969 shares of common stock at a reduced exercise price of $12.92 per share. The gross proceeds to the company from those exercises were approximately $5.9 million (before placement agent fees and estimated offering expenses). The company expects the transactions to close on September 9, 2026, subject to customary conditions.
• In exchange for cash exercise now, the company issued replacement unregistered warrants: Series A Warrants (exercise price $12.67, immediately exercisable, 5‑year term) and Series B Warrants (exercise price $12.67, immediately exercisable, 18‑month term), together covering up to 453,969 shares. H.C. Wainwright & Co., LLC acted as exclusive placement agent, will receive a 7% fee on gross proceeds and was issued placement agent warrants to buy up to 15,889 shares at $16.15 per share.

Key Details

• Aggregate shares subject to the transaction: 453,969 shares; gross cash proceeds ≈ $5.9 million.
• New warrants: Series A (5 years) and Series B (18 months), both exercisable at $12.67 per share.
• Placement agent: H.C. Wainwright; fee = 7% of gross proceeds; placement agent warrants for 15,889 shares at $16.15.
• Beneficial ownership limit: exercises limited so no holder exceeds 4.99% of outstanding shares (can be increased to 9.99% with 61 days’ prior notice).
• Registration: company will file a resale registration (Form S-3 or S-1) for shares issuable on the new warrants within 30 days and use commercially reasonable efforts to have it declared effective (45 days, 60 if full review).

Why It Matters

• This provides Lexaria with near-term cash (~$5.9M) for working capital and general corporate purposes, improving liquidity without a new public offering.
• Investors should note dilution risk: (a) shares were issued on exercise, and (b) replacement warrants give holders the ability to buy additional shares later at $12.67. The placement agent fee and issuance of placement agent warrants also reduce net proceeds and add potential future dilution.
• The registration commitment aims to allow resale of the new warrants’ underlying shares, affecting market liquidity. The beneficial ownership cap limits any single holder from gaining a large immediate stake.